Drug intelligence / Profile preview

JC-013

Development stage: Unknown

Overview

JC-013 is a drug that has completed a Phase 1 clinical trial (NCT06169059) to evaluate its safety and pharmacokinetic characteristics after multiple administrations in healthy adult volunteers. The trial also compared these characteristics with another drug, JLP-2004. Further details regarding its mechanism of action, therapeutic indications, or developers are not provided in the available context.

Beyond the preview

Go deeper on JC-013.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on JC-013.

Explore the full profile